| 英語論文 |
| |
|
1. Wakuda K, Morita M, Sekikawa M, Morikawa N, Miura K, Doshita K, Iida Y, Kodama H, Mamesaya N, Kobayashi H, Ko R, Ono A, Kenmotsu H, Naito T, Murakami H, Muramatsu K, Kawata T, Mori K, Shimizu T, Gon Y, Takahashi T. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing. Int J Clin Oncol. 2024 Feb;29(2):96-102. |
| |
|
2.Iida Y, Wakuda K, Kawata T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Morikawa N, Mamesaya N, Kobayashi H, Ko R, Ono A, Kenmotsu H, Naito T, Murakami H, Gon Y, Takahashi T. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer. Thorac Cancer. 2024 Feb;15(6):477-485. |
| |
|
3. Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Real- World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Target Oncol. 2024 May;19(3):423-433. |
| |
|
4.Iida Y, Wakuda K, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Ko R, Ono A, Naito T, Murakami H, Sugino T, Gon Y, Takahashi T. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma. Sci Rep. 2024 Apr 1;14(1):7641. |
| |
|
5. Kobayashi H. Thoracic lymphangitis as an immune-related adverse event: a case report. BMC Pulm Med. 2024 Jun 25;24(1):299. |
| |
|
6. Kodama H, Murakami H, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ko R, Ono A, Kenmotsu H, Naito T, Matsumoto S, Goto K, Shimizu T, Gon Y, Takahashi T. Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer. Thorac Cancer. 2024 Jul;15(21):1665-1672. |
| |
|
7. Ando K, Naito T, Hamauchi S, Miura K, Nishibori Y, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ryo K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Yamazaki K, Takahashi T. The efficacy and safety of anamorelin among patients with diabetes. Int J Clin Oncol. 2024 Aug;29(8):1115-1121. |
| |
|
8. Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO Clin Res Rep. 2024 Aug 23;5(11):100716. |
| |
|
9. Morikawa N, Naito T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takahashi T. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study. J Geriatr Oncol. 2024 Sep;15(7):101832. |
| |
|
10. Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Kenmotsu H, Naito T, Murakami H, Isaka M, Ohde Y, Takahashi T. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. Cancer Rep (Hoboken). 2024 Sep;7(9):e70004. |
| |
|
11. Doshita K, Naito T, Matsuda S, Morita M, Sekikawa M, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Murakami H, Kenmotsu H, Takahashi T. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study. Thorac Cancer. 2024 Sep;15(25):1831-1841. |
| |
|
12. Kobayashi H, Naito T. PET-CT for visualizing the pathophysiology of COPD in patients with early-stage NSCLC. Thorac Cancer. 2024 Dec;15(34):2456-2457 |
| |
|
13. Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Morikawa N, Miura K, Kodama H, Yabe M, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Takahashi T. Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study. Cancer Treat Res Commun. 2024;41:100849. |
